Ceapro Inc V.CZO

Mr. Market is wrong on this?

[Ciao]

Interesting to note the feature they have in SH under peers.  A lot of comparables are to companies doing research in cancer treatments (high cost for trials, low chance of success). Looking at relative and intrinsic value and seeing where CZO's market cap is at is a test of one's patience and conviction.The recent financials could easily support a stock price much higher than the current share price. 

Collectively insiders do own just under 11% of the shares, and Gilles has exposure to 2.35M shares, Glen Rourke has 1.34M and Don Oborowsky 1.46M.  There is enough skin in the game.

This appears to remain a "show me" story or "tell me the story" story.  Nonetheless this still has all the potential to be a 10 bagger.  Putting this one under the victim of in-efficient markets which allows nimble retail investors to win the stock picker's game in the nano-micro cap space.

[EbbFlow88]

Whatever is coming down the pipeline is still not being valued. The market is waiting to see how this will all be structured and what it looks like in the end. I think regardless, it goes higher. From what we know Gilles has always aimed for his ideal partnership and structure, so I am giving him the benefit of the doubt that he will achieve this. However, even if its not the deal we've all

[Ciao]

Every now and then I need to remind myself that the prize is still the BG pill....

[captwade]

Totally agree with you guys. In this case the market is wrong. There is however, I think, a logical reason that those of us on Stockhouse would feel that way. As I have mentioned here before, thanks to the great sleuthing by some of you, we are among the most knowledgable of CZO shareholders. and, probably logical that we are therefore among the most frustrated. Our day will come, and soon. I

[Ciao]

Captwade, I had to re-listen to the HCW webcast again and if GIlles chooses his words carefully then it appears that PGX-YG could be a breakthrough as a standalone therapy potentially for Covid or just IPF; he said that the German site was for chosen "especially" for PGX Y-BG and "if" it had to be loaded with bioactives, it would be done in Edmonton 1) does this imply that

[Minty_33]

Ciao said...Every now and then I need to remind myself that the prize is still the BG pill.... Spin the wheel, because it could be a total flop. How come there has been zero pre-clinical data released? Can anybody on this board answer that? What about an update of their monoclonal antibodies drying with two big pharma companies which Gilles was said  "a longer term shot" ? (comment

[Ciao]

I'm not a subject matter expert but likely because BG is not a drug, and non toxic so a preclinical study was not needed; in addition there have been more than enough papers on the benefits of BG. If the experts at MHI agreed to put their name on this study, that's good enough for me.  The only concern was it's interaction with statins, but with the change to allow some patients

[Minty_33]

A pretty-clinical study and efficacy evaluation would potentially reduce the costs associated with a full blown study with the MHI if results fell short of expectations. So perhaps they know that the BG pill holds some weight when it come to reducing Cholesterol. How are we to know? Inept IR department and president that doesn't know how to communicate to shareholders and analysts. 

[Ciao]

A pre clinical study would be an additional cost. As mentioned lots of studies have indicated the benefits of BG on reducing LDL and even Health Canada and a few other equivalents in other countries have said the same. I've mentioned this before, any claims on health benefits of a BG pill will be backed by a reputable study and this will be the differentiator when it comes to marketing.

[prophetoffacts]

This post has been removed in accordance with Community Policy